Advertisement

Uterine Cancer pp 369-379 | Cite as

Role of Systemic Therapy in the Management of Uterine Sarcomas

  • Jyoti Bajpai
  • Susan Deepa

Abstract

Uterine sarcomas are a heterogenous group of rare neoplasms with varied histology, clinical behaviour and chemosensitivity [1]. The broad terminology of uterine sarcomas encompasses leiomyosarcoma [LMS], carcinosarcoma, endometrial stromal sarcoma (ESS), and undifferentiated sarcomas [2, 3]. Uterine sarcomas generally have an aggressive clinical behavior, with a tendency for local recurrence and distant spread. Despite high risk of recurrence, the role of adjuvant therapy in uterine sarcoma is still controversial. A phase III randomized trial comparing adjuvant chemotherapy (ACT) to a no-chemotherapy control group is needed to give a final verdict to the management strategy. This chapter will address current management strategies.

Keywords

Overall Survival Gynecologic Oncology Group Uterine Sarcoma Endometrial Stromal Sarcoma Undifferentiated Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

References

  1. 1.
    Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10:1188–98.CrossRefPubMedGoogle Scholar
  2. 2.
    Zaloudek C, Hendrickson M. Mesenchymal tumors of the uterus. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract, vol. 5. New York: Springer; 2002. p. 561–615.Google Scholar
  3. 3.
    Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505.CrossRefPubMedGoogle Scholar
  4. 4.
    Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;62:25–32.CrossRefPubMedGoogle Scholar
  5. 5.
    Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;63:247–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Sartori E, Bazzurini L, Gadducci A, Landoni F, Lissoni A, Maggino T, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol. 1997;67:70–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Hensley ML. Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):773–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Kapp D, Shin J, Chan J. Prognostic factors and survival in uterine leiomyosarcoma. Cancer. 2008;112:820–30.CrossRefPubMedGoogle Scholar
  9. 9.
    Blom R, Guerrieri C, Stâl O, Malmström H, Simonsen E. Leiomyosarcoma of the uterus: analysis of 49 cases. Gynecol Oncol. 1998;68:54–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L. Leiomyosarcoma of the uterus, a clinicopathological multicenter study. Gynecol Oncol. 1999;74:196–201.CrossRefPubMedGoogle Scholar
  11. 11.
    Salazar OM, Dunne ME. The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys. 1980;6:899–902.CrossRefPubMedGoogle Scholar
  12. 12.
    Angelo D, Prat J, et al. Uterine sarcomas: a review. Gynaecol Oncolol. 2010;116:131–9.CrossRefGoogle Scholar
  13. 13.
    Wu TI, Chang TC, Hsueh S, Hsu KH, Chou HH, Huang HJ, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006;100:166–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study. Cancer. 1993;71(4 Suppl):1702–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 2003;23:729–32.PubMedGoogle Scholar
  16. 16.
    Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes. 1999;13:2207–17.CrossRefGoogle Scholar
  17. 17.
    Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler Jr WC, Creasman W, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the gynecologic oncology group). Cancer. 1985;55:1648–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a gynecologic oncology group study. Am J Obstet Gynecol. 1992;166:556–59.CrossRefPubMedGoogle Scholar
  20. 20.
    Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1996;62:226–29.CrossRefPubMedGoogle Scholar
  21. 21.
    Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (doxil) in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2005;96:749–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Look KY, Sandler A, Blessing JA, Lucci 3rd JA, Rose PG, Gynecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2004;92:644–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329–34.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484–92.CrossRefPubMedGoogle Scholar
  26. 26.
    Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890–99.CrossRefPubMedGoogle Scholar
  28. 28.
    Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576–84.CrossRefPubMedGoogle Scholar
  29. 29.
    Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96.CrossRefPubMedGoogle Scholar
  30. 30.
    Grosso F, Sanfilippo R, Jones RL, Collini P, Morosi C, Raspagliesi F, et al. Role of trabectedin (T) in the management of advanced uterine leiomyosarcoma (U-LM). J Clin Oncol. 2009;27:15s, (suppl; abstr 10530).CrossRefGoogle Scholar
  31. 31.
    Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Dinh TA, Oliva EA, Fuller Jr AF, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92:648–52.CrossRefPubMedGoogle Scholar
  33. 33.
    Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol. 1985;3:1240–5.PubMedGoogle Scholar
  34. 34.
    Pautier P, Rey A, Haie-Meder C, Kerbrat P, Dutel JL, Gesta P, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case–control study with radiotherapy alone. Int J Gynecol Cancer. 2004;14:1112–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Hensley ML, Wathen K, Maki RG, Araujo DM, Sutton G, Priebat DA. Adjuvant treatment of high risk uterine leiomyosarcoma with gemcitabine/docetaxel followed by doxorubicin: results of a phase II multi-center trial SARC 005. J Clin Oncol. 2010;28:15s, (suppl; abstr 10021).CrossRefGoogle Scholar
  36. 36.
    Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748–53.CrossRefPubMedGoogle Scholar
  37. 37.
    Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403–14.CrossRefPubMedGoogle Scholar
  38. 38.
    Thigpen JT, Blessing JA, Orr Jr JW, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a gynecologic oncology group study. Cancer Treat Rep. 1986;70:271–4.PubMedGoogle Scholar
  39. 39.
    Merck. Ridaforolimus in treatment of sarcoma—SUCCEED (sarcoma multi-center clinical evaluation of the efficacy of ridaforolimus). Clinical Trials.gov. 2010: NCT00 538239.Google Scholar
  40. 40.
    Di Cello F, Hillion J, Kowalski J, Ronnett BM, Aderinto A, Huso DL, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther. 2008;7:2090–95.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Matsumura N, Mandai M, Miyanishi M, Fukuhara K, Baba T, Higuchi T, et al. Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in-vivo tumorigenesis. Clin Cancer Res. 2006;12:1402–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804–14.PubMedGoogle Scholar
  43. 43.
    Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a gynecologic oncology group study. J Clin Oncol. 1991;9:1962–6.PubMedGoogle Scholar
  44. 44.
    Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol. 1994;53:24–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2000;79:147–53.CrossRefPubMedGoogle Scholar
  46. 46.
    Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2001;83:268–70.CrossRefPubMedGoogle Scholar
  47. 47.
    Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a gynecologic oncology group study. J Clin Oncol. 2007;25:526–31.CrossRefPubMedGoogle Scholar
  48. 48.
    Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. J Clin Oncol. 2010;28:2727–31.PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177–85.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    GOG-261 – A randomized phase III trial of paclitaxel plus carboplatin vs ifosfamide plus paclitaxel in chemotherapy naïve patients with newly diagnosed stage I-IV or persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus, fallopian tube, peritoneum or ovary. ClinicalTrials.gov Identifier: NCT00954174.Google Scholar
  51. 51.
    Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2005;98:217–21.CrossRefPubMedGoogle Scholar
  52. 52.
    Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2010;118:139–44.CrossRefPubMedGoogle Scholar
  53. 53.
    Slayton RE, Blessing JA, DiSaia PJ, Christopherson WA. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a gynecologic oncology group study. Cancer Treat Rep. 1987;71:661–2.PubMedGoogle Scholar
  54. 54.
    Uchida T, Nakakawaji K, Sakamoto J, et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today. 1996;26:138–41.Google Scholar
  55. 55.
    Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007;110:518–20.Google Scholar
  56. 56.
    O’Cearbhaill R, Zhou Q, Iasonos A, et al; Memorial Sloan-Kettering Cancer Center, New York. Evaluation of the role of aromatase inhibitors (Ais) in the treatment of uterine leiomyosarcoma (uLMS). Proc Am Soc Clin Oncol. 2009;27(suppl 15):(abstr 5590).Google Scholar
  57. 57.
    Pink D, Lindner T, Mrozek A, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006;101:464–69.Google Scholar
  58. 58.
    Baggish MS, Woodruff JD. Uterine stromatosis. Clinicopathologic features and hormone dependency. Obstet Gynecol. 1972;40:487–98.Google Scholar
  59. 59.
    Brons J, Jensen LK, Rasmussen J. Hormone treatment of stromal endometriosis. Acta Obstet Gynecol Scand. 1980;59:471–73.Google Scholar
  60. 60.
    Gloor E, Schnyder P, Cikes M, et al. Endolymphatic stromal myosis. Surgical and hormonal treatment of extensive abdominal recurrence 20 years after hysterectomy. Cancer. 1982;50:1888–93.Google Scholar
  61. 61.
    Keen CE, Philip G. Progestogen-induced regression in low-grade endometrial stromal sarcoma. Case report and literature review. Br J Obstet Gynaecol. 1989;96:1435–39.Google Scholar
  62. 62.
    Leunen M, Breugelmans M, De SP, Bourgain C, Amy JJ. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol. 2004;95:769–71.Google Scholar
  63. 63.
    Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 2004;104:1182–84.Google Scholar
  64. 64.
    Makker V, Abu-Rustum NR, Alektiar KM, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008;111:249–254.Google Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Medical OncologyTata Memorial HospitalMumbaiIndia

Personalised recommendations